Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization.
rare diseases
4 major disruptions to the hunt for new cures, and how AI can help
The pursuit of novel cures in the pharmaceutical industry has always been a challenging endeavor. However, within the last decade or so, the landscape has become even more complex and disruptive due to several key factors. In this blog, we explore four major disruptions impacting the hunt for new cures and how artificial intelligence (AI)…
The Impact Review – Founding Vibe Bio
The Impact Review article explores Alok Tayi’s personal experience with rare disease drove him towards a mission – to fund cures for rare diseases.
The Biotech Startups Podcast with guest Alok Tayi, Founder & CEO of Vibe Bio
Learn how Vibe Bio is tackling the problem of funding & guiding high potential drug programs.
Forbes – Alok Tayi’s new start-up is putting drug development into patients’ hands
This article examines how Vibe Bio’s Founder and CEO is putting drug development into patients’ hands.
Endpoint News – Parents become drug developers to save their children’s lives
Endpoint News addressed how parents of children with rare disease are challenging the status quo in drug development.